Krystal Biotech (KRYS) has provided a forecast for its financial activities in fiscal year 2026, highlighting an expectation of non-GAAP research and development (R&D) and selling, general, and administrative (SG&A) expenses ranging from $175 million to $195 million. This projection is a key indicator of the company's commitment to advancing its operational and scientific endeavors. Investors and market analysts are likely to watch closely how these planned investments impact the company's growth and development strategies moving forward.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.